HomeInsightsStock Comparison

Emcure Pharmaceuticals Ltd vs Marksans Pharma Ltd Stock Comparison

Emcure Pharmaceuticals Ltd vs Marksans Pharma Ltd Stock Comparison

Last Updated on: May 03, 2026

Key Highlights

  • The Latest Trading Price of Emcure Pharmaceuticals Ltd is ₹ 1679 as of 30 Apr 15:30 . The P/E Ratio of Emcure Pharmaceuticals Ltd changed from 29.8 on March 2025 to 29.8 on March 2025 . This represents a CAGR of 0.00% over 1 yearsThe P/E Ratio of Marksans Pharma Ltd changed from 8.7 on March 2021 to 26.5 on March 2025 . This represents a CAGR of 24.95% over 5 years The Market Cap of Emcure Pharmaceuticals Ltd changed from ₹ 20327 crore on March 2025 to ₹ 20327 crore on March 2025 . This represents a CAGR of 0.00% over 1 yearsThe Market Cap of Marksans Pharma Ltd changed from ₹ 2044 crore on March 2021 to ₹ 10076 crore on March 2025 . This represents a CAGR of 37.58% over 5 years The revenue of Emcure Pharmaceuticals Ltd for the Dec '25 is ₹ 2365 crore as compare to the Sep '25 revenue of ₹ 2272 crore. This represent the growth of 4.06% The revenue of Marksans Pharma Ltd for the Dec '25 is ₹ 774.57 crore as compare to the Sep '25 revenue of ₹ 741.98 crore. This represent the growth of 4.39% The ebitda of Emcure Pharmaceuticals Ltd for the Dec '25 is ₹ 456.45 crore as compare to the Sep '25 ebitda of ₹ 478.6 crore. This represent the decline of -4.63% The ebitda of Marksans Pharma Ltd for the Dec '25 is ₹ 180.89 crore as compare to the Sep '25 ebitda of ₹ 166.07 crore. This represent the growth of 8.92% The net profit of Emcure Pharmaceuticals Ltd changed from ₹ 152.59 crore to ₹ 231.37 crore over 7 quarters. This represents a CAGR of 26.85% The net profit of Marksans Pharma Ltd changed from ₹ 89.07 crore to ₹ 113.69 crore over 7 quarters. This represents a CAGR of 14.97% The Dividend Payout of Emcure Pharmaceuticals Ltd changed from 4.3 % on March 2021 to 17.92 % on March 2025 . This represents a CAGR of 33.04% over 5 yearsThe Dividend Payout of Marksans Pharma Ltd changed from 10.4 % on March 2021 to 19.26 % on March 2025 . This represents a CAGR of 13.12% over 5 years .

About Emcure Pharmaceuticals Ltd

  • Emcure Pharmaceuticals Limited was originally incorporated as Emcure Pharmaceuticals Private Limited', as a Private Company, pursuant to a Certificate of Incorporation dated April 16, 1981 issued by Registrar of Companies, Maharashtra at Bombay.
  • Subsequently, Company was converted into a Public Company and the name of Company was changed to Emcure Pharmaceuticals Limited', through a fresh Certificate of Incorporation issued by the RoC, Maharashtra in Pune on September 18, 2001. Emcure Pharmaceuticals an Indian pharmaceutical company engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas.
  • In India, they are present across acute and chronic therapeutic areas, and their key therapeutic areas include gynecology, cardiovascular, vitamins, minerals and nutrients, human immunodeficiency virus antivirals, blood-related and oncology/anti-neoplastics.

About Marksans Pharma Ltd

  • Marksans Pharma Limited was formerly incorporated as 'Tasc Pharmaceuticals Limited' in April, 1982.
  • Pursuant to the Scheme of Amalgamation, name of the Company was changed from Tasc Pharmaceuticals Limited to Marksans Pharma Limited from 10th October, 2005.
  • The Company primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulation.
  • The Company's research and development facilities are located in Verna, Goa and R & D center in Navi Mumbai. In 2004-05, the Company amalgamated with M/s.
  • Marksans Pharma Limited (formerly M/s.

FAQs for the comparison of Emcure Pharmaceuticals Ltd and Marksans Pharma Ltd

Which company has a larger market capitalization, Emcure Pharmaceuticals Ltd or Marksans Pharma Ltd?

Market cap of Emcure Pharmaceuticals Ltd is 31,850 Cr while Market cap of Marksans Pharma Ltd is 8,367 Cr

What are the key factors driving the stock performance of Emcure Pharmaceuticals Ltd and Marksans Pharma Ltd?

The stock performance of Emcure Pharmaceuticals Ltd and Marksans Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Emcure Pharmaceuticals Ltd and Marksans Pharma Ltd?

As of May 3, 2026, the Emcure Pharmaceuticals Ltd stock price is INR ₹1679.95. On the other hand, Marksans Pharma Ltd stock price is INR ₹184.65.

How do dividend payouts of Emcure Pharmaceuticals Ltd and Marksans Pharma Ltd compare?

To compare the dividend payouts of Emcure Pharmaceuticals Ltd and Marksans Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions